pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Type 2 Diabetes
drug
save

Type 2 Diabetes

Preclinicalupdated 6mo ago
by Metallomix Inc
Preclinical
community read0 votes

🐶 often sniffed alongside

top 8
  • tagType 2 Diabetes36 co-mentions · 16 sources
  • tagEndocrinology & Metabolism8 co-mentions · 8 sources
  • tagCardiology5 co-mentions · 2 sources
  • tagObesity4 co-mentions · 3 sources
  • tagHeart Failure3 co-mentions · 1 sources
  • drugObesity3 co-mentions · 3 sources
  • tagType 1 Diabetes2 co-mentions · 1 sources
  • drugOzempic2 co-mentions · 2 sources

indications

indications
Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

Trials studying Type 2 Diabetes

  • N/AE3 Diabetes - Closing the Gap in Diabetes Controlactive not recruitingn=150
  • phase3Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancersactive not recruitingn=600
  • N/AImpact of SomaSignal Tests on the Choice of Glucose-lowering Medicationscompletedn=350
  • phase3Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetescompletedn=668

News(10)

  • ObesityWeek 2026: Wave outlines case for body composition–based trial design
    Across three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw s…
    biospace · 2d ago
  • Deep dive: Cardiovascular calamities and catalysts
    BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
    biospace · 5d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 8d ago
  • MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
    FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
    fda_medwatch · 9d ago
  • Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice
    High blood pressure is known as the silent killer. Researchers are finding new ways to fight back.
    stat · 10d ago
  • A treatment revolution is underway in MASH
    To build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patie…
    biospace · 13d ago
  • Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
    Pfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.
    biospace · 14d ago
  • Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
    A phase 2 trial of Ascletis’ oral GLP-1 drug candidate has hit its primary and secondary endpoints, positioning the Chinese biotech to mount a two-front attack on Eli Lilly’s Foundayo.
    fiercebiotech · 20d ago
  • Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
    Eli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expect…
    biospace · 21d ago
  • Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
    Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper reductions in blood sugar and body weight across the 80-week study.
    fiercebiotech · 21d ago
view all news mentions →
indication
Type 2 Diabetes
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?